Home›Emicizumab

Emicizumab

Route: Subcutaneous

2 interactions on record⛔ Black Box Warning

Emicizumab has 2 known drug interactions based on U.S. FDA drug labeling data. 2 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Anti-Inhibitor Coagulant Complex, Factor Ix Complex Concentrates. Patients taking Emicizumab should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 2
Major: 2

Major (2)

Emicizumab + Anti-Inhibitor Coagulant Complex— Clinical experience suggests potential drug interaction exists when FEIBA is used for breakthrough bleeding treatment du…
Emicizumab + Factor Ix Complex Concentrates— Concomitant use with aPCC may result in hypercoagulability. Clinical experience suggests a drug interaction exists betwe…

Emicizumab + Anti-Inhibitor Coagulant Complex⚠️Major

Clinical experience suggests potential drug interaction exists when FEIBA is used for breakthrough bleeding treatment during emicizumab therapy.

Emicizumab + Factor Ix Complex Concentrates⚠️Major

Concomitant use with aPCC may result in hypercoagulability. Clinical experience suggests a drug interaction exists between HEMLIBRA and aPCC.

⛔ FDA Black Box Warning

WARNING: THROMBOTIC MICROANGIOPATHY AND THROMBOEMBOLISM Cases of thrombotic microangiopathy and thrombotic events were reported when on average a cumulative amount of >100 U/kg/24 hours of activated prothrombin complex concentrate was administered for 24 hours or more to patients receiving HEMLIBRA prophylaxis. Monitor for the development of thrombotic microangiopathy and thrombotic events if aPCC is administered. Discontinue aPCC and suspend dosing of HEMLIBRA if symptoms occur. WARNING: THROMBOTIC MICROANGIOPATHY and THROMBOEMBOLISM See full prescribing information for complete boxed warning. Cases of thrombotic microangiopathy and thrombotic events were reported when on average a cumulative amount of >100 U/kg/24 hours of activated prothrombin complex concentrate (aPCC) was administered for 24 hours or more to patients receiving HEMLIBRA prophylaxis. Monitor for the development of thrombotic microangiopathy and thrombotic events if aPCC is administered. Discontinue aPCC and suspend dosing of HEMLIBRA if symptoms occur.

Contraindications

4 CONTRAINDICATIONS None. None ( 4 )

Pregnancy & Breastfeeding

8.1 Pregnancy Risk Summary There are no available data on HEMLIBRA use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. Animal reproduction studies have not been conducted with emicizumab-kxwh. It is not known whether HEMLIBRA can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. HEMLIBRA should be used during pregnancy only if the potential benefit for the mother outweighs the risk to the fetus. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. In the U.S. general population, the estimated background risk of major birth defect and miscarriage in clinically recognized pregnancies is 2 – 4% and 15 – 20%, respectively.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.